This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound ~~Compound~~ of the formula I:



(I)

in which

R^1 represents a (C_6-C_{18})aryl group, which is optionally substituted and/or optionally fused to a saturated or unsaturated, monocyclic or polycyclic 5- to 8-membered nucleus optionally containing one or more hetero atoms chosen from O, N and S, ~~the~~ said nucleus itself being optionally substituted; an optionally substituted, saturated, unsaturated or aromatic 5- to 8-membered monocyclic heterocyclic group containing one or more hetero atoms chosen from O, N and S; an optionally substituted C_2-C_{10} alkenyl group; or a C_1-C_{10} alkyl group~~;~~

R^2 ~~and R^3 independently represent~~ is a hydrogen atom or an optionally substituted (C_6-C_{18})aryl; ~~or alternatively R^2 and R^3 together represent a C_3-C_6 alkylene chain;~~

R^3 is an optionally substituted (C_6-C_{18})aryl; or alternatively R^2 and R^3 together represent a C_3-C_6 alkylene chain;

and

R represents a hydrogen atom; a C_1-C_{10} alkyl group~~;~~ or a (C_6-C_{18})aryl(C_1-C_{10})alkyl group;

~~and the salts~~ or a salt thereof with acids or bases,

or a pharmaceutically acceptable derivative, or stereoisomer thereof, including mixtures thereof in all proportions

~~it being understood that~~ with the proviso that the following compounds are excluded from the protection:

~~when~~ the compounds where R^3 = phenyl~~;~~ , R = ethyl~~;~~ , R^1 = ethyl or phenyl~~;~~ and R^2 = H,

and

methyl (R,S)-2-methoxy-4-phenylbut-3-enoate

~~and also the pharmaceutically acceptable derivatives, solvate derivatives and stereoisomers thereof, including mixtures thereof in all proportions~~.

2. (Currently Amended) A compound ~~Compound~~ according to Claim 1 of the formula I in which R^1 represents a (C_6-C_{10})aryl group, ~~preferably phenyl,~~ which is optionally substituted and/or fused to a carbocyclic or heterocyclic monocyclic 5- to 8-membered nucleus containing from 0 to 4 hetero atoms chosen from O, N and S, which is itself optionally substituted; an optionally substituted C_2-C_{10} alkenyl group; ~~a hydrogen atom;~~

R^2 ~~and R^3 independently represent~~ is a hydrogen atom~~;~~ or (C_6-C_{10})aryl, ~~preferably optionally substituted phenyl;~~ R^3 is a (C_6-C_{10})aryl, or R^2 and R^3 together represent a C_3-C_6 alkylene chain;

and

R represents a hydrogen atom; a C_1-C_{10} alkyl group; a (C_6-C_{10})aryl(C_1-C_{10})alkyl group~~,~~

~~and also the pharmaceutically acceptable derivatives, salts, solvate derivatives and stereoisomers thereof, including mixtures thereof in all proportions~~.

3. (Currently Amended) A compound ~~Compound~~ according to Claim 1, ~~characterised in that~~ wherein when R^1 represents substituted (C_6-C_{10})aryl, the aryl nucleus is substituted by one or more of the following radicals:

trifluoromethyl; a halogen atom; a monocyclic, bicyclic or tricyclic aromatic heterocyclic group comprising one or more hetero atoms chosen from O, N and S~~;~~ , and optionally substituted by one or more radicals T as defined below; a group Het-CO- in which Het represents an aromatic heterocyclic group as defined above, optionally substituted by one or more radicals T; a C_1-C_6 alkylenediyl chain; a C_1-C_6 alkylenedioxy chain; nitro; cyano; (C_1-C_{10})alkyl; (C_1-C_{10})alkylcarbonyl; (C_1-C_{10})alkoxycarbonyl-A- in which A represents (C_1-C_6)alkylene, (C_2-C_6)alkenylene or a bond; (C_3-C_{10})cycloalkyl; trifluoromethoxy; di(C_1-C_{10})alkylamino; (C_1-C_{10})alkoxy(C_1-C_{10})alkyl; (C_1-C_{10})alkoxy; (C_6-C_{18})aryl optionally substituted by one or more radicals T; (C_6-C_{18})aryl(C_1-C_{10})alkoxy-$(CO)_n$- in

which n is 0 or 1 and aryl is optionally substituted by one or more radicals T; $(C_6\text{-}C_{18})$aryloxy$(CO)_n$- in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; $(C_6\text{-}C_{18})$arylthio in which aryl is optionally substituted by one or more radicals T; $(C_6\text{-}C_{18})$aryloxy$(C_1\text{-}C_{10})$alkyl$(CO)_n$– in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; a saturated or unsaturated, monocyclic 5- to 8-membered heterocycle comprising one or more hetero atoms chosen from O, N and S, optionally substituted by one or more radicals T; $(C_6\text{-}C_{18})$arylcarbonyl optionally substituted by one or more radicals T; $(C_6\text{-}C_{18})$arylcarbonyl-B-$(CO)_n$- in which n is 0 or 1; B represents $(C_1\text{-}C_6)$alkylene or $(C_2\text{-}C_6)$alkenylene and aryl is optionally substituted by one or more radicals T; $(C_6\text{-}C_{18})$aryl-C-$(CO)_n$- in which n is 0 or 1, C represents $(C_1\text{-}C_6)$alkylene or $(C_2\text{-}C_6)$alkenylene and aryl is optionally substituted by one or more radicals T; $(C_6\text{-}C_{18})$aryl fused to a saturated or unsaturated heterocycle as defined above, optionally substituted by one or more radicals T; $(C_2\text{-}C_{10})$alkynyl;

T is chosen from a halogen atom; $(C_6\text{-}C_{18})$aryl; $(C_1\text{-}C_6)$alkyl; $(C_1\text{-}C_6)$alkoxy; nitro; carboxyl; $(C_1\text{-}C_6)$alkoxycarboxyl; and T can represent oxo in the case where it ~~substitutes~~ replaces a saturated or unsaturated heterocycle; or alternatively T represents $(C_1\text{-}C_6)$alkoxycarbonyl$(C_1\text{-}C_6)$alkyl; or $(C_1\text{-}C_6)$alkylcarbonyl$((C_1\text{-}C_6)\text{alkyl})_n$- in which n is 0 or 1~~, and also the pharmaceutically acceptable derivatives, salts, solvate derivatives and stereoisomers thereof, including mixtures thereof in all proportions~~.

4. (Currently Amended) A compound ~~Compound~~ according to Claim 1,~~characterised in that~~ wherein when R^1 is aryl, R^1 represents phenyl ~~and also the pharmaceutically acceptable derivatives, salts, solvate derivatives and stereoisomers thereof, including mixtures thereof in all proportions~~.

5. (Currently Amended) A compound ~~Compound~~ according to Claim 1,~~characterised in that~~ wherein R^1 represents $(C_1\text{-}\ C_{10})$ alkyl**,** ~~preferably $(C_1\text{-}C_3)$alkyl,~~ and R^2 and R^3 represent, independently of each other, H or optionally substituted $(C_6\text{-}\ C_{18})$ aryl~~,~~
~~and also the pharmaceutically acceptable derivatives, salts, solvate derivatives and stereoisomers thereof, including mixtures thereof in all proportions~~.

6. (Currently Amended) A compound ~~Compound~~ according to Claim 1, ~~characterised in~~

~~that~~ wherein R^2 is H and R^3 represents unsubstituted aryl~~, preferably unsubstituted phenyl,~~ ~~and also the pharmaceutically acceptable derivatives, salts, solvate derivatives and stereoisomers thereof, including mixtures thereof in all proportions~~.

7. (Currently Amended) A compound ~~Compound~~ according to Claim 1,~~characterised in that~~ wherein when R represents (C_1- C_{10})alkylaryl, ~~preferably benzyl,~~ R^1 and R^3 represent unsubstituted aryl~~, preferably phenyl,~~ ~~and also the pharmaceutically acceptable derivatives, salts, solvate derivatives and stereoisomers thereof, including mixtures thereof in all proportions~~.

8. (Currently Amended) A compound ~~Compound~~ according to Claim 1 of the formula I, which ~~are~~ is:

- ~~methyl (R,S)-2-methoxy-4-phenylbut-3-enoate~~
- (R,S)-2-methoxy-4-phenylbut-3-enoic acid
- methyl (R,S)-2-propoxy-4-phenylbut-3-enoate
- (R,S)-2-propoxy-4-phenylbut-3-enoic acid
- benzyl (R,S)-2-phenoxy-4-phenylbut-3-enoate
- methyl (R,S)-2-trifluoromethylphenoxy-4-phenylbut-3-enoate
- (R,S)-2-phenoxy-4-phenylbut-3-enoic acid
- (R,S)-2-trifluoromethylphenoxy-4-phenylbut-3-enoic acid (Z and E forms),

~~and also the~~ or a pharmaceutically acceptable derivative, salt or stereoisomer ~~derivatives, salts, solvate derivatives and stereoisomers~~ thereof, including mixtures thereof in all proportions.

9. (Withdrawn) Process for the preparation of a compound of the formula I according to Claim 1, characterised in that a halide of the formula R^1-Y in which Y represents a halogen atom and R^1 is (C_1-C_{10})alkyl, is reacted with a compound having the following formula:



in which R^2, R^3 and R are as defined in Claim 1 for formula I, in the presence of silver oxide.

10. (Withdrawn) Process for the preparation of a compound of the formula I according to Claim 1, in which R^1 represents (C_6-C_{10}) aryl, which is optionally substituted and/or optionally fused to a monocyclic heterocyclic saturated or unsaturated 5- to 8-membered nucleus containing one or more hetero atoms chosen from O, N and S, which is itself optionally substituted, characterised in that a compound of the formula:



(V)

in which R^2, R^3 and R are as defined in Claim 1 for formula I, is reacted with a compound of the formula:

R^1-OH

in which R^1 is as defined above, in the presence of rhodium tetraacetate.

11. (Withdrawn) Process for the preparation of a compound of the formula I , characterised in that a compound of the formula as defined in Claim 9 is reacted with a compound of the formula R^1-OH in the presence of triphenylphosphine and ethyl diazodicarboxylate.

12. (Withdrawn) Process for the preparation of a compound of the formula I according to Claim 1, characterised in that a compound of the formula II_{Hal}:



(II_{Hal})

in which R^2, R^3 and R are as defined in Claim 1 for formula I and Hal represents a halogen atom, is reacted with a compound of the formula R^1-OH.

13. (Withdrawn) Process for the preparation of a compound of the formula I according to Claim 3, Hal being a halogen atom, according to the following reaction scheme, the first step being performed in a polar aprotic solvent in the presence of a palladium(0) complex and a base; the second step being a saponification:



in which reaction scheme G represents a monocyclic, bicyclic or tricyclic aromatic heterocyclic group comprising one or more hetero atoms chosen from O, N and S, and optionally substituted by one or more radicals T as defined above when R^1, in the final compound, represents aryl substituted by such a heterocyclic group; or alternatively G represents aryl optionally substituted by one or more radicals T as defined in Claim 3 when, in the final compound, R^1 represents aryl substituted by an aryl group, which is itself optionally substituted by one or more radicals T;

Hal represents a halogen atom

14-15. (Cancelled)

16. (New)A compound according to claim 2, wherein R^1 is (C_1-C_3)alkyl or a phenyl which is optionally substituted and/or fused to a carbocyclic or heterocyclic monocyclic 5- to 8-membered nucleus containing from 0 to 4 hetero atoms chosen from O, N and S, which is itself optionally substituted.

17 (New) A compound according to claim 2, wherein R^2 and R^3 independently represent a substituted or unsubstituted phenyl.

18. (New) A compound according to claim 7, wherein R represents benzyl.